Tale

Follow the glow

Kurt Krause

University of Otago, New Zealand

Published April 29, 2022

By great luck, the laboratory of Kurt Krause, University of Otago, Dunedin, New Zealand is only an eight-minute drive to a waterfall on Nicols Creek famous for an abundance of native glowworms.

A major tourist attraction, glowworms create a starry night effect in wet places—caves, damp areas of forests, and by streams. Glowworms are not actually worms. They are the larvae of fungus gnats that feed on other insects. They snare prey by secreting a curtain of sticky fishing lines with watery beads that they illuminate with blue-green light to attract insects.

The glowworm proximity sparked new life into a side project on the biology of bioluminescence. Researchers in the Krause lab discovered the enzyme that produces the glow—a luciferase related to the one that gives fireflies their green- gold flash (Scientific Reports, 2018). But the glowworm luciferase works with a structurally distinct luciferin molecular partner.

“That has potential ramifications for being a biotechnology tool, but mostly it’s just kind of a cool ‘wow, why does the glow worm glow’ thing,” Krause says. “I've been a part of some cool stuff, just by saying, ‘Yes, okay, let's give it a go.’”

A native Texan, Krause is an infectious diseases physician who discovered structural biology in medical school and eventually became a fulltime scientist. Most of his lab’s research focuses on proteins and enzymes important in diseases spread by bacteria and viruses, such as tuberculosis and coronavirus.

The glutamate racemase protein is a target for potential new antibiotics to treat tuberculosis. The protein cartoon depicts the overall architecture of the protein including potential antibiotic binding sites. The structure, solved in the Krause lab, was chosen for the cover of the Biochemical Journal in 2016. Image courtesy of K.Krause/Otago University

Krause was born in El Paso to parents who married during World War II. His dad was in the U.S. Air Force, so the family moved around when he was growing up. Home videos show Krause’s first major road trip three months after he was born. His mom and dad loaded him, his two brothers, and a Siamese cat named Sissy into a four-door Nash Rambler sedan and drove on a two-lane highway to their new home at the Elmendorf Air Force Base in Anchorage, Alaska.

Later they lived at several bases in Texas, eventually settling in San Antonio where Krause finished high school. He had become interested in science and sped through his college chemistry major, earning a BA by age 19. He played piano seriously and studied the pipe organ, achieving a milestone with J.S. Bach’s Toccata and Fugue in D Minor. A fist fight derailed his keyboard aspirations for a while, but the other guy became a multimillionaire oil and gas tycoon who later funded some of Krause’s research.

Medical school seemed the next logical next step for someone interested in how the human body works, Krause reasoned.

Baylor College of Medicine in Houston was an old-fashioned school, featuring biochemistry, physiology, anatomy, embryology, molecular biology and other courses instead of the case-based curriculum popular today.

“I felt like the whole world opened up in front of me,” he says. “I was seeing protein structures that were just beginning to get solved at that time. It was certainly still quite difficult. And I thought, if you had a protein structure, you had the potential to design a drug. You could design something very specific and very active that presumably wouldn't bind to other proteins.”

By the time he finished medical school, he had decided to get a PhD in protein structure and function. Baylor didn’t offer protein crystallography, so Krause bought an airline pass good for a month or two of unlimited domestic travel. He visited more than one dozen schools across the country, from Stanford to Yale, meeting researchers whose names were familiar from his textbooks.

Choosing Harvard, it was William Lipscomb, a Nobel Laureate, who won over Krause with his teaching style in a class on enzymes.

It was the early 1980s, but Lipscomb had devised a way to display three- dimensional molecular images in the middle of the classroom using two 35- millimeter slide projectors with different polarizing filters. He handed out 3D glasses to students and then walked into the projected image to point out the active site and other features.

“It was awesome. He was so far ahead of his time,” says Krause. “So I joined the lab. It was just the best experience of my life.” “The Colonel,” as he was known to friends and colleagues, had an open-door policy and regular hours (10 am to 4 pm, then 7-10 pm), but he was busy during the day. Krause learned to be at the lab during the evening hours, when The Colonel had time to chat.

Massive by today’s standards, these ATCase crystals launched Krause's career. He grew in them in 1983 for his doctoral thesis. Krause’s research on ATCase was featured in the third and fourth editions of Stryer’s Biochemistry textbook. Image courtesy of K.Krause/Otago University.

The lab was involved in early drug discovery based on the high-resolution structure they had solved of the enzyme carboxypeptidase. Most of Krause’s thesis work was on a larger enzyme, dodecameric aspartate transcarbamoylase.

The glowworm project also traces back to his graduate student days. In search of an interesting collaborative project, Lipscomb asked Krause to be his emissary to the nearby bioluminescence lab of Woody Hastings, igniting a longstanding interest.

After his thesis and a short postdoc, Krause returned to patient care at Baylor, first for a residency in internal medicine and then for his first faculty job. Crystals were growing in the lab, but he had no X-ray equipment. Down the street, J. Andrew McCammon, a University of Houston faculty member, suggested Krause move his crystallography lab there.

With dual academic appointments over the next decade, Krause stepped up the crystallography research while also working part time as a general internal medicine physician. His first structure was the extracellular nuclease that augmented the pathogenicity of Serratia marcescens (Nature Structural Biology, 1994). They quickly obtained crystals that diffracted to 0.88Å, among the highest for that size protein.

The nuclease crystals were so well ordered they diffracted well below 1.0 angstrom. “We could see individual hydrogen atoms,” he says. “We had big plans for trying to use this structure as a way to compare bond-lengths and angles for amino acids within proteins to those from the Cambridge database, which were solved in isolation. But NIH, our initial funder, was not so keen.”

More NIH funding came with a shift to infectious diseases work on antibiotic discovery. The initial focus was on alanine racemase “which everyone hoped would be the perfect drug target. Made sense because D-alanine makes up part of the bacterial cell wall,” he says, “And we don't have any D-alanine in us. If you block a bacteria's ability to make D-alanine, you'll kill it. But if you end up inhibiting the ability for people to produce D-alanine, it's not a problem.”

Unfortunately, they eventually discovered the active site, a tight dimer, was virtually inaccessible to potential drugs.

As his interest in infectious diseases grew, Krause added a clinical fellowship in infectious disease at Baylor to his schedule. It was a pivotal experience.

Most of his early patients had advanced AIDS and died within 6 months. With no proven therapeutics to fight HIV, pandemic deniers challenged the viral origin of the disease, and desperate people promoted useless and dangerous alternative treatments. But soon, a series of controlled clinical trials showed that certain medicines were effective and even more so when used in a triple cocktail.

“It was this incredible experience of seeing all these people dying, transitioning as therapies improved, to almost nobody dying,” he says. “All of a sudden, people had zero viral loads and essentially a normal life expectancy. It was like the scientific method had been validated. Now patients were telling me, ‘Hey, I'm looking for a new job, and I want to get married. And I want to have kids.’ Gamechanger. And it set me up for the more recent [coronavirus] pandemic. I knew that if the research was carried out properly, the proper therapies would be found.”

It was both incredible and unsustainable. Krause was working in the lab during the day and his clinical duties had expanded to include both night HIV clinics and weekend hospital work.

He was negotiating a job offer to set up a new emerging infectious disease center in Ohio when University of Otago called about a biochemistry chair position. On a visit to New Zealand, he found a department staffed with impressive pedigrees from top institutions, some overlapping Krause’s academic family tree. They promised him X-ray equipment. He moved into his new lab in December 2005.

“Our work now is drug discovery and infectious diseases, antiviral and antibacterial, with a side theme in bioluminescence,” he says.

Meanwhile, about halfway through the alanine racemase project, a friend at Chiron, a U.S. biotechnology company acquired by Novartis, called Krause and told him he should be working on glutamate racemase, which has a much more open active site. It turned out that the company was closing down its antibiotic making projects completely. His friend thought the science should continue somewhere.

The tip initially culminated in the structural determination of glutamate racemase from Mycobacterium tuberculosis and Mycobacterium smegmatis (Biochemical Journal, 2016). Now, the Krause lab is looking for targeted inhibitors as new antibiotic candidates. “Every enzyme has its own secret issues,” he says. “The active site of glutamate racemase is open, but still problematic in terms of drug design, but I think we’re found ways around that.”

Krause in his office at University of Otago. The journal on the chair to the left features a structure from Krause's laboratory. Image credit: Finial Riley.

A second drug development project involves BD oxidase. The project has its origins in a 2015 research sabbatical. Krause visited the Frankfurt, Germany, lab of Hartmut Michel, a Nobel Laureate he had met as a graduate student for Lipscomb.

There, Krause worked with Michel’s postdocs on modern membrane protein structural research using cryo-EM. That’s where Krause learned about BD oxidase. Ironically, he discovered that the main research on this protein was being done in New Zealand by Greg Cook, who was already collaborating with Krause on the glutamate project. “He’s just down the hall from me, and I didn’t know he was doing anything on this protein,” Krause says. “I heard about it by going to Germany!”

The collaborators secured a grant and determined the structure (Nature Communications, 2021). “BD oxidase may be the perfect drug target for tuberculosis (TB) drug design,” Krause says. “Now we're trying to see if we can turn this new structure into new drugs for infected patients.”

On his sabbatical, he also was hosted by the Boston lab of Eric Rubin, a tuberculosis researcher at the Harvard School of Public Health and editor of the New England Journal of Medicine. There Krause was first exposed to SBGrid, whose offices are nearby. He embraced the service as a painless solution to the fatigue of maintaining up-to-date software and computing equipment to support structural biology research.

In 2018, Krause invited SBGrid’s Piotr Sliz and Jason Key to an international structural biology meeting in Auckland. Since then, the Krause laboratory has become host for a fledgling hub for SBGrid to expand its services into the Australia-Asia-South Pacific region. The lab has funding and a dedicated SBGrid outreach postdoc.

By now, Krause may know more words in Te Reo, the language spoken by the indigenous Māori people of New Zealand, than the smattering of everyday Spanish he spoke growing up in Texas.

In fact, Krause worked some of the new vocabulary into a recent grant proposal for a research project in bioluminescence. If pressed for a favorite Māori word, he would choose “titiwai,” the name for glowworms, which means “projected over water.”

“Our titiwai work strives to have a focus on kaitiakitanga (guardianship and protection), whanaungatanga (relationships and belonging) and manakitanga (kindness and support),” he explains. The three guidelines also happen to be the mantra of the famous Waitomo Glowworm Caves, whose Māori guardian, or kaitiaki, will perform the same role for the Krause lab.

-Carol Cruzan Morton

Death Metal

Steven Damo

Published 28 April 2024

Context Matters

Bing Chen

Published 30 January 2024
The Crystal Whisperer

Sarah Bowman

Published 29 November 2023

Data in Motion

Nozomi Ando

Published 29 September 2023
The Monstrous Maw

André Hoelz

Published 28 June 2023

Second Takes

Andrea Thorn

Published 28 February 2023
Radical reactions

Yvain Nicolet

Published 31 January 2023

Floppy Physics

Eva Nogales

Published 30 November 2022
Structure of Equity

Jamaine Davis

Published 28 September 2022

Life and Death of a Cell

Evris Gavathiotis

Published 28 July 2022
Follow the glow

Kurt Krause

Published 29 April 2022

Resolution solutions

Willy Wriggers

Published 25 February 2022
Of enzymes and membranes

Ming Zhou

Published 28 October 2021

Step-by-step

Gabrielle Rudenko

Published 26 September 2021
Moving muscle

Montserrat Samso

Published 26 July 2021

Particle catcher

Stefan Raunser

Published 28 June 2021
Designer drugs

Ho Leung Ng

Published 25 February 2021

Right place, right time

Ernesto Fuentes

Published 29 January 2021
Shape-shifting secrets of membranes

James Hurley

Published 27 November 2020

Enzymatic action

Cynthia Wolberger

Published 28 September 2020
Rules of motion

Priyamvada Acharya

Published 31 July 2020

Cosmic Squared

Michael Cianfrocco

Published 27 June 2020
Kaps are Cool

Yuh Min Chook

Published 28 April 2020

Spiraling into focus

Carsten Sachse

Published 29 March 2020
Seeing cilia

Alan Brown

Published 27 February 2020

For the Love of EM

Guy Schoehn

Published 27 January 2020
Protein Puddles

Michael Rosen

Published 16 December 2019

Changing channels

Daniel Minor Jr.

Published 27 September 2019
Listening Tips

Marcos Sotomayor

Published 30 July 2019

Beyond Cool

Published 31 May 2019
Hao Wu

A Higher Order

Published 30 May 2019

Aye Aye Captain

Alexandre Bonvin

Published 29 April 2019
The PARP Family Family

John Pascal

Published 28 February 2019

Frame by frame

Nikolaus Grigorieff

Published 28 January 2019
Predicting Success

Bil Clemons

Published 18 December 2018

Curiouser and Curiouser

Ramaswamy Subramanian

Published 27 November 2018
Rely on This

Sjors Scheres

Published 26 October 2018

Proteins out of bounds

Gerhard Wagner

Published 27 September 2018
Hiding in plain sight

Gaya Amarasinghe

Published 27 July 2018

Jumping Genes

Orsolya Barabas

Published 27 June 2018
Data Whisperer

Karolin Luger

Published 30 May 2018

Flipping the Switch

Jacqueline Cherfils

Published 27 April 2018
Tooling Around

Andrew Kruse

Published 29 March 2018

Comings and Goings

Tom Rapoport, Ph.D.

Published 23 February 2018
Transcriptional Rhythm

Seth Darst

Published 27 January 2018

The Language of Gene Regulation

Daniel Panne

Published 21 November 2017
Not Your Average Protein

James Fraser

Published 23 October 2017

Message Received

Sebastien Granier

Published 24 August 2017
Resistance is Futile

Celia Schiffer

Published 28 July 2017

Twist of Fate

Leemor Joshua-Tor

Published 28 June 2017
Drug Designer

John Buolamwini

Published 30 May 2017

Mathematically Minded

James Holton

Published 28 April 2017
Garbage Out

Kay Diederichs

Published 30 March 2017

Fixer Upper

Brandt Eichman

Published 27 February 2017
Mobilizers

Phoebe Rice

Published 31 January 2017

Escape Artist

Katya Heldwein

Published 19 December 2016
Nature’s Confectioner

Jochen Zimmer

Published 29 November 2016

State of Fusion

Jason McLellan

Published 27 October 2016
Here Be Dragons

Brian Fox

Published 28 September 2016

SBGrid Assumes Ownership of PyMOLWiki

Published 15 September 2016
Pharm Team

Oleg Tsodikov

Published 24 August 2016

Spiro-Gyra

Alejandro Buschiazzo

Published 27 July 2016
Turning the DIALS

Nicholas Sauter

Published 29 June 2016

Pipeline Dreams

Bridget Carragher and Clint Potter

Published 26 April 2016
U-Store-It

The SBGrid Data Bank provides an affordable and sustainable way to preserve and share structural biology data

Published 28 March 2016

Big Questions, Big Answers

Jennifer Doudna

Published 22 February 2016
Not a Structural Biologist

Enrico Di Cera

Published 17 December 2015

Divide and Conquer

Kevin Corbett

Published 19 November 2015
Computing Cellular Clockworks

Klaus Schulten

Published 23 October 2015

Trans-Plant

Gang Dong

Published 26 September 2015
Keep on Moving

James Berger

Published 23 August 2015

Totally Tubular

Antonina Roll-Mecak

Published 27 July 2015
From Disorder, Function

Julie Forman-Kay

Published 29 June 2015

Into Alignment

Geoff Barton

Published 27 May 2015
Two Labs, Many Methods

Michael Sattler

Published 28 April 2015

Picture This

Georgios Skiniotis

Published 20 March 2015
Intron Intrigue

Navtej Toor

Published 20 February 2015

Cut and Paste

Martin Jinek

Published 28 January 2015
Basics and Beyond

Qing Fan

Published 18 December 2014

Bloodletting and Other Studies

Pedro José Barbosa Pereira

Published 25 November 2014
Wire Models, Wired

A brief history of UCSF Chimera

Published 29 October 2014

In Search of…New Drugs

Doug Daniels

Published 30 September 2014
Ilyas Hamdi

Published 30 September 2014

An Affinity for Affinity…and Corals

John C. Williams

Published 29 August 2014
Pete Meyer, Ph.D.

Research Computing Specialist

Published 22 August 2014

Justin O'Connor

Sr. System Administrator

Published 20 August 2014
Carol Herre

Software Release Engineer

Published 15 August 2014

Elizabeth Dougherty

Science Writer

Published 13 August 2014
Andrew Morin, Ph.D.

Policy Research Fellow

Published 11 August 2014

Jason Key, Ph.D.

Associate Director of Technology and Innovation

Published 8 August 2014
Piotr Sliz, Ph.D.

Principal Investigator, SBGrid

Published 1 August 2014

New Kid on the Block

James Chen

Published 29 July 2014
Membrane Master

Tamir Gonen

Published 30 June 2014

The Natural Bridge

Piotr Sliz

Published 13 June 2014
Surprise, Surprise

Catherine Drennan

Published 26 April 2014

Gone Viral

Olve Peersen

Published 20 March 2014
All Who Wander Are Not Lost

Frank Delaglio

Published 24 February 2014

The Raw and the Cooked

Graeme Winter

Published 24 January 2014
Vacc-elerator

Peter Kwong

Published 17 December 2013

Structural Storyteller

Karin Reinisch

Published 15 November 2013
The Fixer

Jane Richardson

Published 28 October 2013

Inside the Box

Mishtu Dey

Published 17 September 2013
Sensing a Change

Brian Crane

Published 16 August 2013

Towards Personalized Oncology

Mark Lemmon

Published 16 July 2013
Brush with Fame

Yizhi Jane Tao

Published 14 June 2013

Toxic Avenger

Borden Lacy

Published 21 May 2013
Pushing the Boundaries

Stephen Harrison

Published 22 April 2013

Strength in Numbers

Joseph Ho

Published 18 March 2013
One Lab, Many Methods

Wesley Sundquist

Published 12 February 2013

Unplanned Pioneer

Tim Stevens

Published 15 January 2013
From Actin to Action

Emil Pai

Published 11 January 2013

Unstructured

A Brief History of CCP4

Published 12 December 2012
Stop, Collaborate and Listen

Eleanor Dodson

Published 5 November 2012

X-PLORer

Axel Brunger

Published 1 October 2012
Share the Wealth

Zbyszek Otwinowski

Published 22 August 2012

Unraveling RNA

Anna Pyle

Published 18 July 2012
Sharper Image

Pawel Penczek and SPARX

Published 4 June 2012

Creative Copy Cat

Pamela Bjorkman

Published 25 April 2012
Charm and Diplomacy

Gerard Kleywegt

Published 7 March 2012

From Curiosity to Cure

Marc Kvansakul

Published 13 December 2011
The Lure of the Sandbox

Paul Emsley and Coot

Published 15 October 2011

Springsteen, Tolkien, Protein

Alwyn Jones and Frodo

Published 17 June 2011
Structures Solved Simply

Paul Adams and Tom Terwilliger on Phenix

Published 2 June 2011

Escape from the Darkroom

Wolfgang Kabsch and XDS

Published 19 May 2011
Playing the Odds

Randy Read and Phaser

Published 19 May 2011

Crystallography for Kids

Lynne Howell

Published 17 May 2011
Better, Faster, Stronger, More

Victor Lamzin and ARP/wARP

Published 17 May 2011

Side-Track to Success

Ning Zheng

Published 13 May 2011

Death Metal

Context Matters

The Crystal Whisperer

Data in Motion

The Monstrous Maw

Second Takes

Radical reactions

Floppy Physics

Structure of Equity

Life and Death of a Cell

Follow the glow

Resolution solutions

Of enzymes and membranes

Step-by-step

Moving muscle

Particle catcher

Designer drugs

Right place, right time

Shape-shifting secrets of membranes

Enzymatic action

Rules of motion

Cosmic Squared

Kaps are Cool

Spiraling into focus

Seeing cilia

For the Love of EM

Protein Puddles

Changing channels

Listening Tips

Beyond Cool

Hao Wu

Aye Aye Captain

The PARP Family Family

Frame by frame

Predicting Success

Curiouser and Curiouser

Rely on This

Proteins out of bounds

Hiding in plain sight

Jumping Genes

Data Whisperer

Flipping the Switch

Tooling Around

Comings and Goings

Transcriptional Rhythm

The Language of Gene Regulation

Not Your Average Protein

Message Received

Resistance is Futile

Twist of Fate

Drug Designer

Mathematically Minded

Garbage Out

Fixer Upper

Mobilizers

Escape Artist

Nature’s Confectioner

State of Fusion

Here Be Dragons

SBGrid Assumes Ownership of PyMOLWiki

Pharm Team

Spiro-Gyra

Turning the DIALS

Pipeline Dreams

U-Store-It

Big Questions, Big Answers

Not a Structural Biologist

Divide and Conquer

Computing Cellular Clockworks

Trans-Plant

Keep on Moving

Totally Tubular

From Disorder, Function

Into Alignment

Two Labs, Many Methods

Picture This

Intron Intrigue

Cut and Paste

Basics and Beyond

Bloodletting and Other Studies